By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) Interleukin Genetics today reported that its fourth-quarter revenues increased 13 percent, driven by a partnership with Amway. The Waltham, Mass.-based genetic test maker had total revenues of $575,339 for the three-month period ended Dec
WALTHAM, Mass.–(BUSINESS WIRE)– Interleukin Genetics,Inc.
NORCROSS, Georgia and LONDON, March 29, 2012 /PRNewswire/ — AKESOgen, the genomics and biorepository services company, and London Genetics International, an expert in the use of pharmacogenetics in drug discovery and development, today announce a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine and provide trans-Atlantic services. The alliance combines world-class expertise and American-European infrastructure to support biopharma drug development.
AMES, Iowa, March 29, 2012 (GLOBE NEWSWIRE) — NewLink Genetics Corporation (Nasdaq:NLNK – News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported financial results for its quarter and year ended December 31, 2011, and provided an update on the progress of its clinical development programs. “2011 was a pivotal year for NewLink,” commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink.
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the upcoming 11th Annual Needham Healthcare Conference in New York, NY
The University of Michigan School of Dentistry and Interleukin Genetics, Inc. (OTCQB: ILIU) announced today the completion of patient enrollment for a landmark clinical study using Interleukin’s PST® Genetic Test to determine if dental patients can be risk-stratified to guide frequency of preventive dental visits and reduce the adverse outcomes of periodontal disease progression, such as tooth …
Natera, formerly known as Gene Security Network, today announced that data from studies of the company’s bioinformatics Parental Support technology will be presented during the American College of Medical Genetics 2012 Annual Clinical Genetics Meeting at the Charlotte Convention Center in Charlotte, North Carolina.
By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) Response Genetics today reported a 23 percent year-over-year drop in revenues for its fourth quarter, driven by a decrease in pharmaceutical client revenue.
The U.S. Supreme Court hasoverturnedMyriad Genetics’ patent onhuman geneslinked to higher risk of breast and ovarian cancers, the AP reported. The decision is yet another in a ping-pong of court rulings on gene ownership, a topic of much interest tomedical researchers and human rights groups alike.
NEW YORK (AP) — Analysts said that this week’s Supreme Court decision to order a new review of patents held by Myriad Genetics Inc. is not bad news for Myriad, and its shares should trade higher. THE OPINION: On Monday the Supreme Court ordered a federal appeals court to conduct a new review of a case that challenges two patents held by Myriad.
Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the full year and fourth quarter ended December 31, 2011.
Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces the First-Step Exome test.
By George Winslow — Broadcasting & Cable, 3/26/2012 5:41:01 PM The PBS special will explore the medical benefits of the genetic revolution and some of the ethical questions raised by these new technologies.
SALT LAKE CITY, March 26, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN – News) reported today that the Supreme Court of the United States remanded the case of The Association for Molecular Pathology, et al., v.
(RTTNews.com) – Myriad Genetics Inc. (MYGN) announced that the Supreme Court of the United States remanded the case of The Association for Molecular Pathology, et al., v. Myriad Genetics Inc., et al to the Federal Circuit Court of Appeals.
BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (Nasdaq:SGEN – News) today announced that the Journal of Clinical Oncology (JCO) published results of the companys pivotal clinical trial of ADCETRIS (brentuximab vedotin) in Hodgkin lymphoma (HL) patients with relapsed or refractory disease following an autologous stem cell transplant (ASCT). The findings, published today online, demonstrated that treatment with ADCETRIS as a single agent induced durable objective responses in 75 percent of patients and was associated with a manageable safety profile
LOS ANGELES–(BUSINESS WIRE)– Response Genetics, Inc. (Nasdaq:RGDX – News), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the addition of Stephanie H.
Public release date: 25-Mar-2012 [ | E-mail | Share ] Contact: Aileen Sheehy as22@sanger.ac.uk 44-122-349-2368 Wellcome Trust Sanger Institute A genetic finding could help explain why influenza becomes a life-threating disease to some people while it has only mild effects in others. New research led by the Wellcome Trust Sanger Institute has identified for the first time a human gene that influences how we respond to influenza infection
ScienceDaily (Mar. 25, 2012) A genetic finding could help explain why influenza becomes a life-threating disease to some people while it has only mild effects in others.
Public release date: 21-Mar-2012 [ | E-mail | Share ] Contact: Phyllis Edelman pedelman@genetics-gsa.org 301-634-7302 Genetics Society of America BETHESDA, MD — The Genetics Society of America (GSA) and the Drosophila community are pleased to announce the nine award recipients for their poster presentations at the 53rd Annual Drosophila Research Conference held March 7-11, 2011 in Chicago, IL.